Melbourne clinicians have uncovered a critical barrier to phage therapy and a fix, after Australia’s first Victorian case showed pre-existing antibodies can neutralise treatment, prompting a shift to routine immune screening.
Researchers from The Alfred and Monash University reported in Nature Medicine that the finding was already reshaping how the therapy is selected and delivered for patients with life-threatening, drug-resistant infections.
The work comes from VICPhage, a joint clinical program spanning The Alfred and Monash University.
It is among the first services in Australia to offer end-to-end phage therapy, from pathogen matching and clinical-grade phage production to bedside administration and trial participation, for infections unresponsive to standard care.
Phage therapy involves administering bacteriophages, viruses that selectively infect and lyse bacteria, as a targeted alternative when antibiotics fail.
